China-based LakeShore Biopharma Co Ltd (Nasdaq:LSB) announced on Wednesday that it has held the 2025 CSO (Contract Sales Organisation) Annual Meeting and the launch meeting of YSJA rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province.

Approved for lot release by regulatory authorities on 15 April 2025, the new formulation will begin nationwide distribution in China within weeks.

The company says that to address pain points such as compounding contamination, occupational exposure of medical staff and needle tip pain, the novel packaging YSJA vaccine has been upgraded accordingly. The novel packaging product is equipped with specially designed clasp, puncture device and suction head, which can realise automatic clamping, needle-free reconstitution and new needle injection, improve the convenience and safety of vaccination, reduce the risk of particle pollution and inflammation, and protect medical staff from needlestick injuries.

"The YSJA packaging innovation represents humanised design in vaccine delivery," said Wang Xu, LakeShore Biopharma CEO. "By leveraging closed sterile connection technology, this novel design will gradually address the industry pain points of 'occupational exposure and pollution risk' in the traditional liquid preparation process. This launch marks the first commercial application of such advanced liquid transfer device in China's rabies vaccine market, filling a significant unmet need."